Leitliniengerechte Therapie: Candidämie/invasive Candidiasis

  title={Leitliniengerechte Therapie: Candid{\"a}mie/invasive Candidiasis},
  author={Andreas Gl{\"o}ckner},
Invasive Mykosen werden auf der Intensivstation hauptsächlich durch Arten der Gattung Candida verursacht und treten zumeist als Candidämie auf. Trotz verbesserter therapeutischer Möglichkeiten in den letzten zwei Jahrzehnten ist die Letalität der invasiven Candidiasis mit 20 bis 50% weiterhin hoch. Seit Anfang des Jahrtausends steht mit den Echinocandinen eine weitere Klasse von Antimykotika zur Verfügung, dessen Wirkspektrum die klinisch relevanten Spezies von Candida und Aspergillus umfasst… Expand
1 Citations
Současné možnosti antimykotické léčby invazivní kandidózy na jednotkách intenzivní péče
Althoughantifungal prophylaxis lowers the incidence of invasive candidiasis, it is considered to be useful only if targeted to high-risk groups of patients, and empirical treatment of febrile patients not responding to broad-spectrum antibiotic therapy is only effective in wards with a higher incidence of systemic candidiasis. Expand


Treatment of invasive candidiasis with echinocandins
Echinocandins have a favourable tolerability profile and exhibit a minimal potential for drug interactions since their pharmacokinetics is independent of renal and hepatic function, and are appropriate drugs of choice for invasive candidiasis in intensive care where many patients experience organ failure and receive multiple drugs with complex interactions. Expand
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Micafungin was as effective as--and caused fewer adverse events than--liposomal amphotericin B as first-line treatment of candidaemia and invasive candidosis. Expand
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
Voriconazole was as effective as the regimen of amphotericin B followed by fluconazole in the treatment of candidaemia in non-neutropenic patients, and with fewer toxic effects. Expand
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
  • P. Pappas, C. Rotstein, +14 authors D. Buell
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
Dosages of micafungin 100 mg daily and 150 mg daily were noninferior to a standard dosage of caspofungin for the treatment of candidemia and other forms of invasive candidiasis. Expand
Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection. Expand
Anidulafungin in the treatment of patients with invasive candidiasis.
Once the Candida species is identified and its susceptibility is determined, clinicians should consider step-down therapy to either fluconazole or voriconazole, with possible conversion from intravenous to oral therapy. Expand
Comparison of caspofungin and amphotericin B for invasive candidiasis.
Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia. Expand
Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.
Adequate empirical therapy is used in a minority of patients with invasive Candida spp. Expand
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.
In patients without neutropenia and without major immunodeficiency, fluconazole and amphotericin B are not significantly different in their effectiveness in treating candidemia. Expand
Anidulafungin versus fluconazole for invasive candidiasis.
Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis, and the statistical analyses failed to show a "center effect". Expand